Clinical outcomes of bortezomib-based therapy in myeloma

Bortezomib, a first generation proteasome inhibitor, is used in both newly diagnosed and relapsed myeloma settings. Considerable differences exist in the usage of bortezomib therapy in the clinical practice setting in comparison to clinical trial setting as well manufacturer’s recommendations. These...

Descripción completa

Detalles Bibliográficos
Autores principales: Djebbari, Faouzi, Srinivasan, Anandagopal, Vallance, Grant, Moore, Sally, Kothari, Jaimal, Ramasamy, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291151/
https://www.ncbi.nlm.nih.gov/pubmed/30540831
http://dx.doi.org/10.1371/journal.pone.0208920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291151/
https://www.ncbi.nlm.nih.gov/pubmed/30540831
http://dx.doi.org/10.1371/journal.pone.0208920

Ejemplares similares